Expression of 3q Oncogene SEC62 Predicts Survival in Head and Neck Squamous Cell Carcinoma Patients Treated with Primary Chemoradiation.

Cancers (Basel) · 2023 · PMC10778380 · PMID 38201525

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Recently, a pan-cancer analysis using DNA sequencing data from over 40,000 patients showed that SEC62 gene amplification represents a highly significant indicator of poor overall survival [ 21 ].

also in 132,142 other papers

a slight trendno p-value reported

Regarding a potential correlation between SEC62 expression and response to treatment according to RECIST 1.1 criteria, no significant difference in SEC62 levels was seen between patients with complete remission (CR), partial remission (PR), stable disease (SD), and progressive disease (PD), with only a slight trend towards lower SEC62 levels in CR patients compared to non-CR patients (PR + SD + PD; Figure 1 F).

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.